Amgen Posts Financial Results for Q4 2011

Amgen reported fourth quarter total revenue rose 3% to $4 billion.

Biotech company Amgen announced last week its financial results for the fourth quarter of 2011.

The company's U.S. product sales were up 5% to $3.0 billion in the quarter, and up 4% to $11.7 million for the year. International product sales in the quarter were $900 million (+1%), and $3.6 million for the year (+5%).

Combined Neulasta and Neupogen sales were $1.3 billion (+7%) in the quarter and up 8% to $5.2 billion for the year. Enbrel sales were $945 million (+1%) in the quarter and $3.7 billion for the year (+5%). Aranesp sales were down 15% to $538 million in the quarter, due to a unit decline, and down 7% to $2.3 billion for the year, due to a high-teens percentage point unit decline in the U.S. Epogen sales were down 18% to $486 million in t